Cardiol Therapeutics Inc Class A has seen notable movements this week, with recent developments impacting its stock performance.
Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a slight uptick of 1.55% on Friday, but the stock has faced a significant decline of 17.09% over the past week. This volatility comes amidst important corporate news and ongoing developments in the health care sector.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$316.13M
52W high
$3.23
52W low
$1.23
1W change
-17.09%
Beta
0.61
Analyst Price Targets
Based on analyst covering CRDL · as of Sep 17, 2026
Wall Street analysts forecast CRDL stock price to rise 129.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+129.0% Upside
Current Price
C$2.62
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
79.1%
Annualized
90-Day Vol
62.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.16
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.80 | C$2.13 – C$3.68 |
| 60 trading days | C$2.97 | C$2.02 – C$4.37 |
| 90 trading days | C$3.16 | C$1.97 – C$5.06 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should pay attention to Cardiol's recent capital-raising activities and ongoing clinical trials, as these factors could influence the company's financial health and growth potential in the long run.
C$2.64 Last Close, 1D: +1.55%
Cardiol's stock has shown a remarkable year-to-date increase of 92.65%, despite recent fluctuations and a weekly decline.
Bull case
The recent exercise of share purchase warrants has improved Cardiol's financial position, bringing in over USD $7 million to support its Phase III clinical trials. This funding could boost investor confidence and lead to more positive developments in the future.
Bear case
Even with the recent capital raise, the company's negative profit margins and high return on equity (ROE) might make some investors cautious. The stock's recent drop could reflect market skepticism about its future performance.
Recent Price Action
Cardiol Therapeutics Inc Class A closed at C$2.64 on Friday, reflecting a modest increase of 1.55% for the day. However, the stock has seen a more significant decline of 17.09% over the past week, raising questions about market sentiment.
Catalysts Impacting Performance
Advertisement
Recent headlines indicate that Cardiol Therapeutics has exercised outstanding common share purchase warrants, raising over USD $7 million. This funding is earmarked to support the company's Phase III MAVERIC trial, which aims to address heart disease. Additionally, the company filed a preliminary base shelf prospectus for USD $150 million, indicating plans for potential future offerings. Such moves are crucial for extending its cash runway into H1 2028.
Technical Picture
From a technical standpoint, Cardiol's stock is currently trading above its 50-day moving average of C$2.21 by approximately 19.6% and above its 200-day moving average of C$1.72 by about 53.7%. The stock's 52-week range is C$1.23 to C$3.23, indicating it is currently trading at 71% of its range. With a beta of 0.61, the stock has been less volatile than the market overall. Recent trading volume has been relatively steady, with the latest volume at 221,614 shares, slightly below the 20-day average of 296,088 shares.
Insider Activity
No recent insider activity has been reported for Cardiol Therapeutics, which could suggest stability in management and ownership.
Price Action Summary
As of the last close, Cardiol Therapeutics Inc Class A is trading at C$2.64, reflecting a 1D increase of 1.55%. The stock's YTD performance remains strong at +92.65%, despite the recent weekly decline.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
